[go: up one dir, main page]

NO20054034L - Fremgangsmate for behandling av hypotyroidisme. - Google Patents

Fremgangsmate for behandling av hypotyroidisme.

Info

Publication number
NO20054034L
NO20054034L NO20054034A NO20054034A NO20054034L NO 20054034 L NO20054034 L NO 20054034L NO 20054034 A NO20054034 A NO 20054034A NO 20054034 A NO20054034 A NO 20054034A NO 20054034 L NO20054034 L NO 20054034L
Authority
NO
Norway
Prior art keywords
hypothyroidism
procedures
treatment
adults
dose
Prior art date
Application number
NO20054034A
Other languages
English (en)
Other versions
NO20054034D0 (no
Inventor
Irwin Klein
Kaie Ojamaa
Sara Danzi
Original Assignee
Long Island Jewish Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Long Island Jewish Res Inst filed Critical Long Island Jewish Res Inst
Publication of NO20054034D0 publication Critical patent/NO20054034D0/no
Publication of NO20054034L publication Critical patent/NO20054034L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for behandling av hypotyroidisme hos voksne omfattende langvarig administrering av T3 i en dose på 0,005-0,03 µg/kg kroppsvekt/time/dag.
NO20054034A 2003-02-11 2005-08-30 Fremgangsmate for behandling av hypotyroidisme. NO20054034L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/364,800 US20040156893A1 (en) 2003-02-11 2003-02-11 Method for treating hypothyroidism
PCT/US2004/003620 WO2004071432A2 (en) 2003-02-11 2004-02-06 Method for treating hypothyroidism

Publications (2)

Publication Number Publication Date
NO20054034D0 NO20054034D0 (no) 2005-08-30
NO20054034L true NO20054034L (no) 2005-10-05

Family

ID=32824502

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054034A NO20054034L (no) 2003-02-11 2005-08-30 Fremgangsmate for behandling av hypotyroidisme.

Country Status (9)

Country Link
US (2) US20040156893A1 (no)
EP (1) EP1599193A4 (no)
JP (1) JP2006517588A (no)
AU (1) AU2004211961B2 (no)
BR (1) BRPI0407410A (no)
CA (1) CA2515400A1 (no)
CO (1) CO5650242A2 (no)
NO (1) NO20054034L (no)
WO (1) WO2004071432A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
IL298365A (en) * 2020-05-21 2023-01-01 Equilibrate Therapeutics Llc Microneedle device to control thyroid hormone levels
US12451021B2 (en) 2022-08-04 2025-10-21 The Mitre Corporation Microscale weather hazard products for urban aviation transportation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3477954A (en) * 1966-06-29 1969-11-11 Armour Pharma Phosphonium iodide complexes of thyroxine,methods of preparing same,and methods of preparing 3,5,3'-l-triiodothyronine therefrom
US3577535A (en) * 1966-06-29 1971-05-04 Armour Pharma Treatment of thyroid hormone impairment pharmaceutical compositions containing 3,5,3' -l-triiodothyronine complexes
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
US3689669A (en) * 1970-10-09 1972-09-05 Univ Of North Carolina The Antidepressant method and composition
US3928553A (en) * 1972-03-23 1975-12-23 Univ New York Radioimmunoassay method for triiodothyronine and thyroxine
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5158978A (en) * 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
ATE164063T1 (de) * 1991-12-30 1998-04-15 Akzo Nobel Nv Thyroaktive zusammensetzung mit kontrollierter freigabe
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US6288117B1 (en) * 2000-03-23 2001-09-11 North Shore-Long Island Jewish Research Institute Method for treating congestive heart failure
US20020183882A1 (en) * 2000-10-20 2002-12-05 Michael Dearing RF point of sale and delivery method and system using communication with remote computer and having features to read a large number of RF tags
US20030194437A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Cmax properties

Also Published As

Publication number Publication date
CO5650242A2 (es) 2006-06-30
AU2004211961A1 (en) 2004-08-26
NO20054034D0 (no) 2005-08-30
EP1599193A4 (en) 2007-04-04
US20040156893A1 (en) 2004-08-12
CA2515400A1 (en) 2004-08-26
WO2004071432A3 (en) 2005-03-10
BRPI0407410A (pt) 2006-02-21
WO2004071432A2 (en) 2004-08-26
AU2004211961B2 (en) 2009-04-23
EP1599193A2 (en) 2005-11-30
JP2006517588A (ja) 2006-07-27
US20050176829A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
EP1587506A4 (en) ADMINISTRATION OF CAPSAICINOIDS
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
BR0316753A (pt) Método de tratamento para disfunção sexual
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
ZA200608407B (en) Method and composition for treating rhinitis
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
PL1603584T3 (pl) Aplidyna do leczenia szpiczaka mnogiego
NO20062857L (no) Farmasoytisk preparat omfattende et sink-hyaluronatkompleks for behandling av multippel sklerose
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
TW200512000A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteopenia or male osteoporosis
WO2005060978A3 (en) Polymetaphosphate based formulations for therapy of microcrystalline arthropathies

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application